Shreya Nandi, Sohini Das

Stories by Shreya Nandi, Sohini Das

Gujarat gets lion's share of Covid vaccines

Gujarat gets lion's share of Covid vaccines

Rediff.com   4 May 2021

Delhi, which has been one of the worst affected states, accounted for less than two per cent of total vaccinations in the 18-44 age-group.

Covid wave: Govt speeds up import approval for 17 medical equipment

Covid wave: Govt speeds up import approval for 17 medical equipment

Rediff.com   30 Apr 2021

Recently, the finance ministry waived off basic customs duty and health cess on imported oxygen and related equipment for three years.

Covid vaccine: Too early to say if booster dose needed

Covid vaccine: Too early to say if booster dose needed

Rediff.com   30 Apr 2021

Initial data has shown immunity triggered by the two mRNA vaccines -- Pfizer-BioNTech and Moderna -- lasts for at least six months

Covid vaccine could cost up to Rs 1000 in private market

Covid vaccine could cost up to Rs 1000 in private market

Rediff.com   28 Apr 2021

While the Indian government has been procuring Covid-19 vaccines at low prices so far, manufacturers have to declare the prices of vaccines they would supply to the open market (industries, private hospitals, etc) and state governments before May 1. Sohini Das reports.

A COVID-19 Vaccine Snapshot

A COVID-19 Vaccine Snapshot

Rediff.com   28 Apr 2021

Sputnik V is already approved in India and Sinovac is unlikely to come in as it does not meet the criteria.

Where is the manpower to handle ventilators?

Where is the manpower to handle ventilators?

Rediff.com   25 Apr 2021

The second wave of the pandemic has not only crippled medical infrastructure in terms of hospital beds, but has also led to bottlenecks in invasive ventilators and medical oxygen capacities and supplies.

Demand for Covid-19 tests growing 100 pc week-on-week

Demand for Covid-19 tests growing 100 pc week-on-week

Rediff.com   23 Apr 2021

One challenge for many laboratories in ramping up is the shortage of trained manpower for collecting samples, report Sohini Das, Vinay Umarji and Virendra Singh Rawat.

Shortage of key chemical from US hits Covaxin ramp-up plans

Shortage of key chemical from US hits Covaxin ramp-up plans

Rediff.com   22 Apr 2021

'In case of shortage of other raw material, like filters and bags, one can try to develop another vendor. However, for chemicals as critical as adjuvants, this is not possible'

Serum, Bharat Biotech to get Rs 45 bn for 300 mn vaccines

Serum, Bharat Biotech to get Rs 45 bn for 300 mn vaccines

Rediff.com   20 Apr 2021

This will be an upfront payment for the vaccine doses that these two companies will supply to the government.

COVID-19 vaccine: Why Poonawalla wrote to Biden

COVID-19 vaccine: Why Poonawalla wrote to Biden

Rediff.com   17 Apr 2021

'The US has invoked the Defence Act and banned export of raw materials.' 'This is as good as banning vaccines.'

100 million Covaxin vaccines by Sept

100 million Covaxin vaccines by Sept

Rediff.com   17 Apr 2021

The production of Covaxin will increase from the current 10 million doses per month to 60 million-70 million by July-August.

Second Covid wave is 1.7x times faster than first wave, shows data

Second Covid wave is 1.7x times faster than first wave, shows data

Rediff.com   15 Apr 2021

It has taken 51 days to reach a daily caseload of 84,000 from 11,000, as against 85 days taken in the first wave, report Abhishek Waghmare and Sohini Das.

Rising Covid cases cast shadow on exports

Rising Covid cases cast shadow on exports

Rediff.com   14 Apr 2021

According to Ajai Sahai, director-general and CEO of Federation of Indian Export Organisations, rising cases are a cause for concern as it adds to the uncertainty and may impact exports.

'We will be prioritising vaccine only for India'

'We will be prioritising vaccine only for India'

Rediff.com   14 Apr 2021

'I don't think anybody would want to be in my position today where every head of State has to be explained that I am prioritising my country because there is a surge in cases.'

Serum, Bharat Bio seek govt funds to boost vaccine output

Serum, Bharat Bio seek govt funds to boost vaccine output

Rediff.com   5 Apr 2021

Both manufacturers have sought funds in excess of Rs 150 crore under the department of biotechnology's Mission Covid Suraksha scheme. Announced last November, the scheme has an outlay of Rs 900 crore to help develop Covid vaccines, from the clinical development stage to setting up production sites.

Expert panel seeks more data on Sputnik V Covid vaccine

Expert panel seeks more data on Sputnik V Covid vaccine

Rediff.com   2 Apr 2021

'No approval was given to Sputnik V on Thursday. Some queries have been asked on safety, efficacy, and logistics, which the firm will have answers to at the next meeting'

Sputnik V vaccine may be added to India's Covid armoury soon

Sputnik V vaccine may be added to India's Covid armoury soon

Rediff.com   30 Mar 2021

'We expect to get the approval in the next few weeks,' says Deepak Sapra, CEO, API and pharmaceutical services, Dr Reddy's Laboratories (DRL).

How Modi govt plans to protect domestic manufacturers

How Modi govt plans to protect domestic manufacturers

Rediff.com   30 Mar 2021

The central government is devising a mechanism to step up screening imports to protect domestic manufacturers. The details of the online monitoring system may find mention in the foreign trade policy 2021-26, which will kick in next month. The online system will make the data available to the government as well as industry about the countries from where the goods are being imported, and their quantity and quality. The data can help domestic producers analyse the market potential for such goods, said a senior government official. In the past 16 months, the government had implemented a steel- and coal-import monitoring system.

Draft e-commerce policy is 'nationalistic'

Draft e-commerce policy is 'nationalistic'

Rediff.com   22 Mar 2021

Many industry executives have said the draft e-commerce policy is being perceived as nationalistic but not overly protectionist and it is providing preference to Indian players against foreign companies. This might have an impact on investment by large players such as Walmart and Amazon in the country, said the executives. They said e-commerce was a very small portion of the retail industry and at a nascent stage and did not require heavy hammer regulations. Though the policy talks about being equally applicable to foreign and domestic players, it mentions that foreign direct investment (FDI) takes precedence over the e-commerce policy in any area of overlap.

Bharat Biotech's Krishna Ella wins Covaxin fight

Bharat Biotech's Krishna Ella wins Covaxin fight

Rediff.com   22 Mar 2021

'He came back from the US only to work for his country.' 'He has invested his fortunes to build this company and is married to his work.' 'Rarely does one see such commitment.'